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Summary
Renal stone disease often begins by renal colic. In order to
manage this event adequately, several goals should be pur-
sued: first, attenuate pain; second, favour progression and
spontaneous expulsion of stones; third, prevent from obstruc-
tive and infectious complications. All of the aforementioned
points pertain to medical management of this disease. 
Concerning prevention, it is widely agreed that pathogenesis
of kidney stones is a consequence of abnormalities in urine
environment, leading to a disequilibrium between promoters
and inhibitors of crystallization. Therefore, the rationale for
therapy is to make urine less conductive to stone formation,
by both decreasing state of saturation and increasing inhibito-
ry potential. 
In only some types of stone-forming salts it is possible to ob-
tain undersaturation with the solid phase. Indeed, uric acid
stones can be chemically dissolved by using alkali and allop-
urinol. To a lesser extent, this also applies to cystine stones,
with the use of thiols and alkali. In these subsets, the afore-
mentioned tools are also effective to prevent new stone for-
mation. 
Much more challenging appears the treatment of calcium con-
taining stones. About 10% of such stones is caused by sys-
temic disorders and, in these cases, the prevention of new
stones is successfully accomplished by curing the underlying
disease. For instance, parathyroidectomy cures calcium
nephrolithiasis in case of hyperparathyroidism. 
However, the majority of patients with calcium stones are idio-
pathic stone-formers, in whom metabolic abnormalities often
occur, namely, hypercalciuria, hyperoxaluria, hypocitraturia.
The correction of these abnormalities by using thiazide diuret-
ics, alkaline citrates, potassium phosphate and bisphospho-
nates is based on the prevailing metabolic defect. Among the
most recent available tools, Oxalobacter Formigenes and pro-
biotics have been proposed to treat primary or secondary hy-
peroxalurias. 
In general, the treatment of stone disease reduces its recur-
rence rate, but only seldom results in stable remission. Any-
way, less stones mean reduction of the need for urological
procedures and the associated infective or obstructive com-
plications. 
Of course, medical prevention implies financial efforts, but a
careful cost to benefit analysis demonstrates that these are
well justified. 
KEY WORDS: renal colic, nephrolithiasis, thiazides, alkali citrate, bisphos-
phonates, oxalobacter formigenes.
Introduction
The very first manifestation of renal stone disease is often repre-
sented by renal colic. This event requires patients be managed
adequately pursuing several goals: first, attenuate pain; second,
favour progression and spontaneous expulsion of stones; third,
prevent from obstructive and infectious complications. 
Subsequently, after resolution of the acute episode, patients
should be considered for prevention of new stones or, in partic-
ular cases, for dissolution of existing stones. 
All of the aforementioned points pertain to medical manage-
ment of this disease, and will be the object of the present re-
view. 
Medical management of renal colic
Pain relief
Patients with renal colic are more frequently seen in emer-
gency units, where physicians are asked to attenuate flank
pain which is often much troublesome. Therapeutic options in
this respect include spasmolytic, opioids, nonsteroidal anti-in-
flammatory drugs (NSAIDs). Efficacy of either drugs is mainly
dependent on individual response, though NSAID such as ke-
torolac, alone or in association with morphine, have given
better results to reduce pain (1). It is now agreed that fluid in-
fusion should be limited to restore the fluids lost with sweat-
ing and vomiting, which often accompany renal colic, in order
to both reduce hydronephrosis and avoid to untowardly in-
crease flank pain. Conversely, anti-diuresis has been carried
out using desmopressin spray, usually in combination with
other analgesic drugs, to obtain pain relief with favourable re-
sults (2). 
Stone expulsion
Many papers have recently been published supporting the effi-
cacy of medical expulsion therapy with alpha-adrenoceptor an-
tagonists or calcium channel antagonists. Among the former,
tamsulosin was shown to increase the rate of spontaneous
stone passage by approximately 50% for small distal stones. In
a randomized perspective study in patients with distal ureteral
stones, tamsulosin gave an expulsion rate of 97.1% vs 77.1%
of nifedipine (p < 0.0001). These patients achieved stone pas-
sage in a shorter time and showed a significantly decreased
number of hospitalizations and endoscopic procedures. Alone
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or in association with NSAIDs, tamsulosin also appeared to de-
crease the severity of renal colic (3).
This issue was addressed in a recent review of papers report-
ing expulsion facilitation of moderately sized, distal, ureteral
stones. Treatments with alpha-antagonists or calcium-channel
blockers were compared to a standard therapy group in studies
that reported stone expulsion rates. A pooled analysis of 16
studies using an alpha-antagonist and 9 studies using a calci-
um-channel blocker suggested that the addition of each of
these agents, compared to standard therapy, significantly im-
proved spontaneous stone expulsion (relative risk 1.59 vs 1.50
and number needed to treat 3.3 vs 3.9, for alpha-antagonists
and calcium channel blockers, respectively). Subgroup analy-
sis of trials using concomitant medications such as low-dose
steroids yielded a similar improvement in stone expulsion rate.
Adverse effects were only minor and rare. It was concluded
that expulsive therapy, using either alpha-antagonists or calci-
um channel blockers increased the stone expulsion rate (4). 
Prevention of obstructive and infectious complications 
In a previous paper we reported that obstruction and infection,
connected to invasive urological procedures, were the major
causative factors of renal insufficiency in patients with recurrent
stone disease (5). The occurrence of renal insufficiency has
been likely abated with the use of modern non-invasive proce-
dures, but attention should still be paid to the association be-
tween obstruction and infection, which represents a threat for
the development of urosepsis. When a patient with renal colic
is suspected to progress to this dangerous complication, he
should urgently be referred to an urologist in order to remove
the obstruction, either temporarily (ureteral stenting) or ulti-
mately (ureteroscopic ESWL, ureterolitholapaxy). 
Any way, timely and aggressive antibiotic therapy, moderate
hydration and close follow-up of patient’s chemistries and
imaging are mandatory. 
Medical management of the kidney stone disease
Renal stones are thought to be caused by abnormalities in urine
environment, namely, an imbalance between promoters and in-
hibitors of stone formation. This in turn depends on abnormali-
ties of the most relevant urine constituents. Therefore, the med-
ical management is aimed at normalizing these derangements,
to reduce the risk of forming new stone. This is accomplished
by either reducing urine state of saturation with respect to a giv-
en salt or increasing urine inhibitor activity, or both. 
A brief review of the current medical therapies of renal stone
disease is reported below. 
Uric acid and cystine stones
In only some types of stones it is possible to obtain undersatu-
ration with the solid phase. Indeed, uric acid stones can be
chemically dissolved by using alkali and allopurinol. To a lesser
extent, this also applies to cystine stones, with the use of thiols
and alkali. In these subsets the aforementioned tools are also
effective to prevent new stone formation. 
In a recent review of Guidelines of Renal Stones by the AURO
(Associazione Urologi Ospedalieri), the medical treatment of
uric acid and cystine stones was set as follows (6): 
Uric acid stones: 
a. bring urine pH at > 6.0 by using sodium bicarbonate (30-40
mg/kg body weight daily) or potassium citrate (1-2 mEq/kg
b.w./day) or sodium citrate (same dosages);
b. reduce urinary concentration of uric acid by diluting with high
fluid intake, or with allopurinol (150 mg/day), only in hyperurico-
suric patients. 
Cystine stones: 
a. maintain urine pH between 7.0 and 7.5, by using sodium bi-
carbonate, potassium or sodium citrate;
b. reduce cystine concentration at < 1 mmol/L (300 mg/L) by
using any type of thiols, such as thiopronine (20 mg/kg/day) or
D-penicillamine (12-15 mg/kg/day);
c. the disappearance of spontaneous crystalluria can be taken
as an index of efficacy of medical treatment (7). 
In patients with good compliance to the above advice it is pos-
sible to obtain stable remission of the stone disease. Surpris-
ingly, despite clear cut physicochemical evidence of the effica-
cy of medical therapy, for both types of stones there are no
prospective evidence-based studies on this issue. 
Calcium nephrolithiasis 
Much more challenging appears the treatment of calcium con-
taining stones. About 10% of such stones is caused by sys-
temic disorders and, in these cases, the prevention of new
stones is successfully accomplished by curing the underlying
disease. For instance, parathyroidectomy cures or greatly im-
proves calcium nephrolithiasis in the course of hyperparathy-
roidism (8). 
However, in case of the so-called idiopathic calcium
nephrolithiasis, remission of the disease is not a rule. In addi-
tion to problems arising from a poor patients’ compliance to
therapy, the fact that defined cause(s) of the disease is not
straightforward explains the unsatisfying outcomes or failures
in medical management. 
To partly overcome these difficulties, many Centres adopt diag-
nostic protocols designed to ascertain metabolic abnormalities,
which may guide the choice of prescribed therapy (9, 10).
Table I lists the drugs currently used in patients with calcium
nephrolithiasis, and the recognized rationale for their use. 
Apart from the pathophysiological evidence suggesting bene-
ficial effects to counteract the stone disease, whether drugs
be actually effective to reduce recurrence rate is not definitely
established. In fact, due to the nature of the disease, charac-
terized by unpredictable periods of active disease and pro-
longed relapses, it is very difficult to obtain evidence based
data on the effects of a given drug on the natural history of
nephrolithiasis. Indeed, very few placebo-controlled random-
ized studies are so far available. An incomplete list of ran-
domized trials, performed by using thiazide diuretics is given
in Table II. It can be seen that the follow-up were relatively
short, the number of patients enrolled low, the baseline stone
recurrence not much high. Anyway, quite all the quoted stud-
ies reported significant reduction of the severity of stone dis-
ease, but complete remissions were obtained only in a part of
the patients, with a significant advantage with treatment in
some but not all studies (11). The same applies to trials
which used alkali citrate (Table II). 
A more recent meta-analysis on trials concerning the efficacy
of alkali citrate to prevent calcium oxalate nephrolithiasis con-
sidered 43 papers, written in English or German, and enrolling
up to 1000 patients. Overall, citrate reduced recurrence rate by
47% to 100%; in 4 randomized studies conducted on 227 pa-
tients, 53.5% vs 35% remained stone-free over 1 year, with cit-
rate and placebo, respectively (12). Of interest was also the
finding the alkali citrate favoured dissolution or clearances of
residual fragments after ESWL (66% vs 27.5%, p < 0.0001). 
However, if not for other reasons, validation to the use of alka-
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line citrate salts comes from findings supporting favourable ef-
fects on bone mineralization (13). 
Quite recently, the presence of Oxalobacter Formigenes was
shown to be associated with a 70% reduction of the risk of being
a calcium stone former (14). The mechanism of these anaerobic
bacteria is to promote oxalate catabolism in the intestine, there-
by preventing intestinal absorption and urinary excretion. This is
likely to apply to patients in which nephrolithiasis is associated
with inflammatory bowel disease and cystic fibrosis. The hypoth-
esis that patients with idiopathic stone disease have an in-
creased oxalate excretion due to a decreased intestinal colo-
nization by these bacteria deserves further investigations.
Conclusions
Medical management of patients with urolithiasis is crucially
important for their outcome. The principal goals of medical ef-
forts are manifold as listed below: 
1. relief pain during renal colic;
2. favour spontaneous expulsion of ureteral stones;
3. prevent formation or growth of renal stones;
4. reduce the need of urologic procedures; 
5. reduce the occurrence of complicating events, such as in-
fection and/or obstruction;
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Table I - Drugs currently used for the prevention of calcium nephrolithiasis and their rationale. 
Drug Indications Actions
Thiazide diuretics Hypercalciuria Decrease in urine calcium 
Improved bone turnover
Slight decrease of urine citrate
Alkali citrate salts Hypocitraturia Increase in urine citrate 
Acidic urine pH Increase in urine pH 
Mild decrease in urine calcium
Allopurinol Hyperuricosuria Decrease in urate excretion
Bisphosphonates Dietary independent hypercalciuria associated Decrease fasting calciuria
with high bone turnover Less marked decrease in 24-hr calciuria
Potassium phosphate Phosphate leak hypercalciuria Increase serum phosphate 
Increase urine phosphate 
Possible increase in urine pyrophosphate
Oxalobacter Formigenes Primary or enteric hyperoxaluria Decrease oxalate excretion 
and other probiotics
Table II - Randomized trials on the efficacy of thiazide diuretics on the prevention of calcium stone disease. 
Author Follow-up Nr. of patients Stone/pt/year % Remissions P
Therapy Placebo Therapy Placebo Therapy Placebo
Ohkawa, 1992 2 82 93 0.13 0.31 86.5 55.9 <0.05
Brocks, 1981 4 33 29 0.09 0.11 84.8 82.8 n.s.
Scholz, 1982 1 25 26 0.20 0.20 760. 76.9 n.s.
Ettinger, 1988 4 23 31 0.05 0.22 870. 54.8 <0.05
Lerum Larsen, 1984 3 23 25 0.07 0.18 78.3 52.0 0.05
Wilson, 1984 3 23 21 0.15 0.31 – – 0.05
Robertson, 1985 3 13 09 0.22 0.58 – – sign
Borghi, 1993 3 19 21 0.06 0.28 84.2 57.1 <0.05
Table III - Randomized trials on the efficacy of alkali citrate for the prevention of calcium oxalate nephrolithiasis. 
Author Follow-up Nr. of patients Stone/pt/year % Remissions P
Therapy Placebo Therapy Placebo Therapy Placebo
Barcelo, 1993 3 18 20 0.1 1.1 72.2 20.0 <0.05
Hofbauer, 1994 3 16 22 0.9 0.7 31.3 27.3 n.s.
Ettinger, 1997 3 16 25 – – 87.1 36.4 RR=0.16
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6. prevent renal tissue injury;
7. avoid onset and progression of renal insufficiency. 
That therapy may significantly improve the natural course of
stone disease has been definitely stated for some but not all
the aforementioned issues. The nature of this disease, espe-
cially the idiopathic calcium nephrolithiasis, requires that relat-
ed studies be designed so as to enrol a large number of pa-
tients to be treated over a long term follow-up.
References
11. Safdar B, Degutis LC, Landry K, Vedere SR, Moscovitz HC,
D’Onofrio G. Intravenous morphine plus ketorolac is superior to ei-
ther drug alone for treatment of acute renal colic. Ann Emerg Med.
2006;48:173-181. 
12. Lopes T, Dias JS, Marcelino J, Varela J, Ribeiro S, Dias J. An as-
sessment of the clinical efficacy of intranasal desmopressin spray
in the treatment of renal colic. BJU Int. 2001;87:322-325.
13. Dellabella M, Milanese G, Muzzonigro G. Randomized trial of the
efficacy of tamsulosin, nifedipine and phloroglucinol in medical ex-
pulsive therapy for distal ureteral calculi. J Urol. 2005;174:167-72.
14. Singh A, Alter HJ, Littlepage A. A systematic review of medical
therapy to facilitate passage of ureteral calculi. Ann Emerg Med.
2007;50:552-63. 
15. Marangella M, Bruno M, Cosseddu D, Manganaro M, Tricerri A,
Vitale C, Linari F. Prevalence of chronic renal insufficiency in the
course of idiopathic recurrent calcium stone disease: risk factors
and patterns of progression. Nephron. 1990;54:302-6.
16. Guideline on Urinary Stones 2007. Ass. Urologi Italiani. Auro.it. 
17. Daudon M, Cohen-Solal F, Barbey F, Gagnadoux MF, Knebel-
mann B, Jungers P. Cystine crystal volume determination: a useful
tool in the management of cystinuric patients. Urol Res. 2003;31:
207-11.
18. Mollerup CL, Lindewald H. Renal stones and primary hyper-
parathyroidism: natural history of renal stone disease after suc-
cessful parathyroidectomy. World J Surg. 1999;23:173-5. 
19. Marangella M, Vitale C, Bagnis C, Bruno M, Ramello A. Idiopathic
calcium nephrolithiasis. Nephron. 1999; 81 Suppl 1:38-44.
10. Pak CY, Peterson R, Poindexter JR. Adequacy of a single stone
risk analysis in the medical evaluation of urolithiasis. J Urol. 2001;
165:378-81.
11. Pearle MS, Roehrborn CG, Pak CY. Meta-analysis of randomized
trials for medical prevention of calcium oxalate nephrolithiasis. J
Endourol. 1999;13:679-85. 
12. Mattle D, Hess B. Preventive treatment of nephrolithiasis with al-
kali citrate. A critical review. Urol Res. 2005;33:73-9
13. Marangella M, Di Stefano M, Casalis S, Berutti S, D’Amelio P, Isa-
ia GC. Effects of Potassium Citrate Supplementation on Bone Me-
tabolism. Calcif Tissue Int. 2004;74:330-5.
14. Kaufman DW, Kelly JP, Curhan GC, Anderson TE, Dretler SP,
Preminger GM, Cave DR. Oxalobacter formigenes May Reduce
the Risk of Calcium Oxalate Kidney Stones. J Am Soc Nephrol.
2008; Mar 5 [Epub ahead of print].
134 Clinical Cases in Mineral and Bone Metabolism 2008; 5(2): 131-134
M. Marangella et al.
©
 C
IC
 E
DI
ZI
ON
I I
NT
ER
NA
ZI
ON
AL
I
